drugset / Trial / NCT04366648
Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor
RandomizedSequentialDouble-blindTreatment
Summary
The purpose of this clinical trial is to evaluate the safety and tolerability of injectable PEG-Irinotecan in patients with malignant solid tumors
Timeline
- Start
- 2018-05-04
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JK-1201I | Unknown | 50 mg/m2 | — |
| Subject | JK-1201I | Unknown | 75 mg/m2 | — |
| Subject | JK-1201I | Unknown | 100 mg/m2 | — |
| Subject | JK-1201I | Unknown | 125 mg/m2 | — |
| Subject | JK-1201I | Unknown | 150 mg/m2 | — |
| Subject | JK-1201I | Unknown | 180 mg/m2 | — |